Kornimate/medical-research-clean huggingface dataset:
study of cerebrospinal fluid samples in diagnosing carcinomatous meningitis in patients with cancer or meningeal syndrome

Conditions: Brain and Central Nervous System Tumors; Breast Cancer; Metastatic Cancer

Summary: rationale: studying samples of cerebrospinal fluid from patients with cancer or meningeal syndrome may help doctors identify biomarkers related to cancer. purpose: this clinical trial is studying cerebrospinal fluid samples in diagnosing carcinomatous meningitis in patients with cancer or meningeal syndrome.

objectives: primary * evaluate the validity of determining ca 15-3 levels in the cerebrospinal fluid (csf) using automated immuno-enzymatic methods. secondary * determine the sensitivity and specificity of these assays in assessing ca 15-3 in csf. * assess favorability of intrathecal production of ca 15-3. * determine threshold interpretations of ca 15-3 levels in csf. outline: this is a multicenter study. within 15 days of suspected meningeal involvement, blood and cerebrospinal fluid samples are collected. samples are examined by immunoenzyme assays. patients with suspected cases of carcinomatous meningitis undergo cerebrospinal mri.

Eligibility criteria:
disease characteristics: * meets 1 of the following criteria: * diagnosis of metastatic breast cancer with evidence suggestive of carcinomatous meningitis, with or without brain metastasis * other type of cancer with evidence suggestive of carcinomatous meningitis * meningeal syndrome without context of cancer patient characteristics: * no other prior cancers * not pregnant or nursing prior concurrent therapy: * no prior intrathecal treatment * at least 4 weeks since prior interferon * no concurrent participation in another clinical trial

Keywords: leptomeningeal metastases male breast cancer stage iv breast cancer tumors metastatic to brain adult meningioma
italian multicenter retrospective observational study on transformed lymphomas

Conditions: Non-Hodgkin Lymphoma Transformed Recurrent

Summary: study purpose is to evaluate treatment outcome and survival in patient with aggressive lymphomas transformed from follicular lymphoma.


Eligibility criteria:
inclusion criteria: * histologically confirmed transformed follicular lymphoma * age \> 18 years * histological transformation between january 2002 and december 2014 * availability of data about treatment and outcome exclusion criteria: * other lymphoma diagnosis

Keywords: non-hodgkin lymphoma transformed recurrent discordant lymphomas composite lymphomas follicular lymphoma aggressive lymphoma
knee replacement and sarcopenia

Conditions: Sarcopenia; Knee Prosthesis; Knee Arthroplasty, Total

Summary: the presence of sarcopenia in patients planned to undergo knee prosthesis and the effect of knee prosthesis on sarcopenia will be investigated

volunteer patients who will undergo knee replacement surgery in orthopedic clinics located in the istanbul region and who meet the inclusion criteria will be recruited. a total of 31 volunteers will be included in the study. first, all patients will be asked about their gender, age, height, weight, education, smoking, lifestyle, additional diseases, and treatments they have received. then, a brief orthopedic evaluation will be performed on the patient. tanita bia analysis and grip strength measurement from the dominant hand will be performed on all patients before the operation, at 1 month and 3 months after the operation. maximal voluntary grip strength will be measured with a hand dynamometer. measurements will be made three times. for this measurement, the subject will be asked to hold a maximal voluntary grip for five seconds. there will be a ten-second rest period between the three tests. measurements will be made with the jamar plus+ (by sammons preston) hand dynamometry device. before the test measurements, the patient will be shown how to use the device as an application. the highest of the three measured values will be taken. in addition, the calf circumference will be measured. while the patient is standing, the measurement will be made with a tape measure from the thickest point of the right and left calves without squeezing the skin. the same measurement will be repeated with the patient seated. at the same time, patients will be evaluated with walking speed test, sit-to-stand test, sarc-f, frail frailty questionnaire, mini nutritional assessment, eq-5d general quality of life scale, glim test, barthel activities of daily living index, cirs scale before the operation, 1st month and 3rd month after the operation. when performing the walking speed test, the patient will be asked to walk as they normally do. a 4-meter or 3-meter walking speed test will be performed and a single test will be scored. measurements will be made twice and the fastest will be evaluated. in the sit-to-stand test, the person will be asked to try to get up without using their arms. if they cannot complete the test or can get up using their arms, the patient will receive 0 (zero) points. if they can get up using their arms, the repeated sit-to-stand test will be performed. in the repeated sit-to-stand test, the person will be asked to sit down and get up from a chair 5 times in a row without using their arms. scoring will be between 0-4 depending on the time spent.

Eligibility criteria:
inclusion criteria: * being between 50-75 years old * undergoing knee arthroplasty surgery * patients who agreed to participate in the study and gave written consent exclusion criteria: * having a history of malignancy * being under 50 and over 75 years old * having one of the muscle/nerve diseases
burden of nintedanib non-adherence among idiopathic pulmonary fibrosis (ipf) patients

Conditions: Idiopathic Pulmonary Fibrosis

Summary: this study has two objectives: 1. to assess the association between nintedanib adherence trajectory group (as measured from a group-based trajectory modelling (gbtm)) and health care resource use, with a focus on inpatient hospitalization, among patients with idiopathic pulmonary fibrosis (ipf). 2. to assess the association between a patient's nintedanib adherence trajectory group (as measured from a gbtm) and their medical costs among patients with ipf.


Eligibility criteria:
inclusion criteria: * newly initiated nintedanib during 10/01/2014 to 12/31/2018 * were at least 66 years old as of the date of their first nintedanib prescription claim (index date) * qualified for medicare based on age * had at least 12 months of continuous enrollment in medicare parts a, b and d before (baseline period) and 12 months after the index date (follow-up period) * had at least one inpatient or two outpatient claims (\>14 days apart) with a diagnosis code for ipf (icd-10-cm: j84.112; icd-9-cm: 516.31) during the baseline period exclusion criteria: * had any history of pirfenidone or nintedanib use during the baseline period * had any history of lung transplant during the baseline, index date or follow-up periods * had any claims for skilled nursing facility, long-term care facility or hospice during the baseline, index date or follow-up period * had evidence (≥2 icd-9-cm or icd-10-cm diagnosis codes on different dates) during the baseline period of any of the following conditions: lung cancer, autoimmune, or connective tissue diseases (i.e., rheumatoid arthritis (ra), sarcoidosis, systemic lupus erythematosus (sle), dermatopolymyositis, systemic sclerosis, sjogren's, and mixed connective tissue disease (ctd)) during the baseline period * had dual eligibility of medicare and medicaid * had history of using pirfenidone at the same time with nintedanib during follow-up
safety study of an oral vitamin d analog in postmenopausal women

Conditions: Postmenopausal Osteoporosis, Multiple Sites

Summary: determine the safety of 2md, a vitamin d analog, when administered orally once daily for 28 days in healthy normal postmenopausal women.


Eligibility criteria:
inclusion criteria: 1. normal healthy postmenopausal women, ≥ 60 but ≤ 80 years of age, or between 45 and 60 years of age who have been amenorrheic for at least 2 years plus have a serum fsh level of \> 30 iu/l, or women with a documented bilateral oophorectomy at least 2 years prior to study start. 2. within ±30% of their ideal body weight for height and body frame. 3. demonstrated ability to understand and willingness to sign an informed consent form. 4. 24-hour urinary ca ≤250 mg/day and a urinary ca:cr ≤0.35. 5. negative urine test for selected drugs of abuse. 6. willing to maintain a total calcium intake between 700 and 1000 mg/day. exclusion criteria: 1. any acute or chronic condition that would limit the subject's ability to complete the study. 2. active clinical manifestations of significant metabolic, hematological, pulmonary, hepatic, cardiovascular, gastrointestinal (including malabsorption), neurological, renal, urological or psychiatric disorders. 3. history or presence of any diseases known or believed to influence calcium absorption or metabolism. 4. history of renal calculi. 5. history of an eating disorder. 6. history of stomach or intestinal surgery. 7. history of hypersensitivity or allergies to any vitamin d derivative. 8. history or presence of an abnormal ecg. 9. use of any medications or products affecting vitamin d metabolism within 6 months prior to study entry. 10. use of any medications or products affecting calcium balance or bone turnover within 6 months prior to study entry. 11. participation in any other investigational study drug trial in which receipt of investigational study drug occurred within 60 days prior to study entry. 12. use of vitamin and/or mineral supplements \>1x rdi within 4 weeks prior to study entry, unless deemed acceptable by investigator. 13. poor peripheral venous access. 14. receipt of blood products within 2 months prior to study entry. -

Keywords: vitamin d analog
the effects of a sub-maximal exercise program on adolescents who sustained a concussion

Conditions: Concussion, Mild; Concussion, Brain; Concussion, Severe; Exertion; Excess

Summary: patients who sustain a concussion will undergo a sub-maximal exercise protocol throughout their recovery. cerebrovascular function, heart rate, and symptom severity, and exercise volume will be monitored throughout.

there has been recent change to the management of concussion, including the addition of exercise while a patient may still be experiencing symptoms. some patients will be given a dose-dependent exercise prescription based on their own sub-maximal output. they will aerobically exercise at this given threshold for 8 weeks, while heart rate and symptom duration is tracked. some patients will only follow physician prescribed exercise, while undergoing the same heart rate and symptom monitoring for 8 weeks.

Eligibility criteria:
inclusion criteria: * experienced a concussion within the last 2 weeks. concussion will be diagnosed by board-certified sports medicine physicians, and defined as a direct or indirect blow to the head, face, neck, or elsewhere that manifests with the presence of symptoms and neurological impairment * low or moderate cardiac risk according to american college of sports medicine * post-concussion symptom scale (pcss) score greater than 9 exclusion criteria: * history of neurological surgery * seizure disorder * use of medication or medical device that would alter heart rate, blood pressure or autonomic function * any current, serious, chronic medical or psychiatric disease that, in the principal investigator's judgment, may interfere with study participation or data integrity * unable or unwilling to provide informed consent
prediction on the recurrence of manic and depressive episodes in bipolar disorder

Conditions: Bipolar Disorder; Depressive Disorder

Summary: mood disorders (including bipolar disorder and major depressive disorder) are chronic mental disorders with high recurrent rate. the more the number of recurrence is, the worse long-term prognosis is. this study aims to establish a prediction model of recurrence of manic and depressive episodes in mood disorders, with a hope to detect recurrence relapse as early as possible for timely clinical intervention. we will adopt wearable smart watch to collect heart rate, sleep pattern, activity level, as well as emotional status for one year long in 100 patients with bipolar disorder, and annotated their mood status (i.e., manic episode, depressive episode, and euthymic state). we expect to establish prediction models to predict the recurrence of mood episodes.


Eligibility criteria:
inclusion criteria: * dsm-5 bipolar disorder or depressive disorder * 20\~60 years old * willing to carry smartwatch and smartphone most of the time exclusion criteria: * comorbid with substance use disorder * unable to use smartwatch and smartphone

Keywords: biomarker bipolar disorder
study comparing enbrel (etanercept) plus methotrexate versus enbrel alone in active rheumatoid arthritis despite current methotrexate therapy

Conditions: Rheumatoid Arthritis

Summary: to investigate the changes in mri-derived markers of joint inflammation and destruction and in biochemical markers of connective tissue metabolism and angiogenesis in rheumatoid arthritis patients treated with enbrel and enbrel+methotrexate.


Eligibility criteria:
inclusion criteria: * in the case of contra-indications for mri, the patient may participate in the remaining part of the project. exclusion criteria: * n/a

Keywords: rheumatoid arthritis
coronary atherosclerosis t1-weighted characterization (catch)

Conditions: Coronary Atherosclerosis

Summary: this study proposes to develop an mri technique named coronary atherosclerosis t1-weighed characterization (catch) that will improve the quality and reliability of coronary atherosclerosis evaluation, as well as simplify the scanning process and significantly shorten imaging time compared with conventional imaging methods.

approximately 100 healthy male/female adult "normals" or "controls" and 40 male/female adult outpatients who are suspected of having or have been diagnosed with coronary artery disease will be recruited. all subjects will be asked to undergo either a non-contrast mri or a contrast-enhanced mri of the coronary artery depending upon the focus of development at the time of their participation it is anticipated that healthy volunteers will undergo non-contrast or contrast-enhanced mri for evaluating the image quality associated with each acquisition module of the developed technique and motion artifact associated with motion compensation strategy. for subjects receiving contrast, a total dose of up to 0.2 mmol/kg of a gadolinium based contrast agent will be injected intravenously provided all the safety requirements are met. subjects undergoing a contrast-enhanced mri will be screened using the standard clinical protocol to determine whether it is safe to administer contrast. if subjects do not qualify for contrast administration, they may be asked to have a research scan without contrast. research mri results will be compared with clinical diagnostic ct and/or invasive imaging studies for patients who have been evaluated with these exams at cedars-sinai medical center..

Eligibility criteria:
inclusion: * healthy volunteers: male or female ≥ 18 years of age with a bmi\<30, with no history of cardiovascular disease * patients: medically stable, male or female ≥ 18 years of age who is have not suspected of having or has been diagnosed with coronary artery disease and undergone stenting or bypass surgery exclusion: * contraindications to mr imaging including mechanically, magnetically, or electrically activated implants, ferromagnetic implants and ferromagnetic foreign bodies, pregnancy. * inability to tolerate mr imaging secondary to an inability to hold breath for a short time or have claustrophobia. * non-compliant with visit instructions, including following procedure instructions * severe allergy to animal dander or animal-instigated asthma * specific to gadolinium-based contrast agents: renal function test does not meet csmc standard of care mri contrast protocol requirements (gfr \<45ml/min) or previous allergic reaction to gadolinium-based contrast agents.\* * volunteers who have had four or more prior previous gadolinium contrast scan

Keywords: mri technique high resolution mri technique
effect of patient position on computerized tomography guided celiac trunk neurolysis

Conditions: Upper Abdominal Malignancy

Summary: computerized tomography-guided celiac plexus neurolysis has become a popular technique. as, it has cross-section imaging system to avoids anatomic structures injury, it has high density resolution that clearly display the retro-peritoneal anatomic structures ,it allow an optimal puncture site selection and measured the angle and depth of the needle insertion accurately with display the range of the neurolytic agent diffusion

the aim of this study was to evaluate analgesic efficacy of a computerized tomography guided left lateral antero-crural approach near the origin of celiac trunk with patients position on their right side immediately after the procedure using a single needle injection technique for upper abdominal malignancy compared with the classic 2 needle posterior antero-crural injection technique and possible complications. all patients will take thin computerized tomography section in the axial plane to detect the site of celiac plexus and coronal plane for correct site for needle placement. computerized tomography slices thickness will be from 3 mm at 5mm interval through all the abdominal and lower thoracic area. the celiac and superior mesenteric arteries will be identified after contrast injection. when an ideal needle position and tip were confirmed, the stylet was removed and aspiration was performed to ensure that there was no blood is withdrawn. a volume of 3 ml of lidocaine mixed with contrast was injected to confirm the position, after injection another cut has been taken to show the spread of contrast freely in the retro-peritoneal space around the celiac plexus and the aorta. after confirmation, that contrast was injected to surround the artery and make sure that there was no dorsal spread to avoid injury to somatic nerves. also to make sure that there was no spread to the renal pelvis , injection of phenol 10% mixed with contrast through needle

Eligibility criteria:
inclusion criteria: * patients with gastric carcinoma * patients with hepato-biliary-pancreatic cancer * patients with colonic malignancy * patients with peritoneal metastasis * patients with extensive hepatic metastasis * patients having intractable pain to opioids and other analgesics. * patients experienced adverse effects to opioids or other analgesics. * patients experienced improved intractable pain after diagnostic celiac plexus block exclusion criteria: * patient's refusal * patients with bleeding tendency * patients with coagulopathy * patients who were benefited from oral analgesics with no serious side effects * patients with significant cardiac diseases * patients with organ failure * patients with distant vertebral metastasis * evidence of local infection at the puncture site * patients who did not experience improved pain after receiving a diagnostic celiac plexus block
mycophenolate mofetil and tacrolimus versus tacrolimus for the treatment of idiopathic membranous glomerulonephritis

Conditions: Glomerulonephritis, Membranous

Summary: study hypothesis: when mycophenolate mofetil is added to tacrolimus in the treatment of membranous glomerulonephritis it is likely to improve the initial response to treatment and reduce the risk of relapse on stopping therapy.

membranous nephropathy is a common cause of nephrotic syndrome in adults. it is difficult to treat and if persistent leads to end stage renal failure in a significant number of patients. it is currently treated in this institution with tacrolimus monotherapy. this is effective in the majority of patients in reducing proteinuria but the remissions are often partial and patients tend to relapse when the tacrolimus treatment is stopped. we propose to use mycophenolate mofetil in combination with tacrolimus with the aim of obtaining a more complete initial response to treatment, a decreased rate of relapse on withdrawal of therapy and less progression of renal failure. this will be a randomised control trial, patients will be randomised to receive treatment with tacrolimus alone (our current standard therapy)or treatment with tacrolimus and mycophenolate mofetil. participants will receive treatment for up to 2 years and then be monitored for relapse of their nephrotic syndrome.

Eligibility criteria:
inclusion criteria: * idiopathic membranous glomerulonephritis on renal biopsy * proteinuria - protein/creatinine ratio (pcr) \> 100 units with hypoalbuminaemia or pcr \> 300 units with normal serum albumin despite 3 months treatment with maximum tolerated doses of ace inhibitors and angiotensin 2 antagonists (or shorter if life threatening complications of nephrotic syndrome require institution of immediate immunosuppression) * male or female patients aged 18 to 80 years exclusion criteria: * hepatitis b hepatitis c or hiv positive * malignancy (all patients must have a ct chest abdomen and pelvis and other investigations if clinically indicated) * untreated infection * females who are pregnant, breast feeding, or at risk of pregnancy and not using a medically acceptable form of contraception * any condition judged by the investigator that would cause the study to be detrimental to the patient

Keywords: glomerulonephritis
confident treatment decisions in living with rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: pilot test the novel educational patient-directed intervention to demonstrate the feasibility of the novel educational approaches developed in improving patient's willingness to achieve remission or low disease activity in ra.

pilot test the novel educational patient-directed intervention to demonstrate the feasibility of the novel educational approaches developed in improving patient's willingness to achieve remission or low disease activity in ra. upon agreement to participate, the patient participants will provide information on their treating physician. this information will be used to invite physicians to complete the physician-educational intervention and offered cme credits for completing the activity. the investigators will recruit participants from a patient registry (1:1 intervention: control) that meet the eligibility criteria. the recruited patients will complete the educational intervention (if randomized to the intervention arm) and the study outcomes will be collected immediately after the intervention and also after the patients most proximate rheumatologist visit (up to 6-months later).

Eligibility criteria:
inclusion criteria: * have a patient-reported diagnosis of ra * most recent rapid3 \> 12 collected in the last 6 months * have not changed ra medication in the last 6 months * taking medications that are commonly used in ra (e.g. methotrexate, sulfasalazine, hydroxychloroquine (plaquenil), leflunomide (arava), etanercept (enbrel), adalimumab (humira), tofacitinib (xeljanz), actemra (tocilizumab), sarilumab (kevzara) , infliximab (remicade), golimumab (simponi), rituximab (rituxan), abatacept (orencia), and certolizumab (cimzia)) exclusion criteria: * does not meet inclusion criteria * age \< 18